VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 76 filers reported holding VAXCYTE INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,390,517 | -17.2% | 18,415 | -25.1% | 0.00% | 0.0% |
Q1 2024 | $1,680,221 | +21.6% | 24,597 | +11.8% | 0.00% | 0.0% |
Q4 2023 | $1,382,103 | +25.3% | 22,008 | +1.7% | 0.00% | 0.0% |
Q3 2023 | $1,102,799 | -0.3% | 21,632 | -2.4% | 0.00% | 0.0% |
Q2 2023 | $1,106,471 | +70.6% | 22,156 | +28.0% | 0.00% | – |
Q1 2023 | $648,704 | -26.7% | 17,308 | -6.3% | 0.00% | -100.0% |
Q4 2022 | $885,253 | +158.8% | 18,462 | +29.4% | 0.00% | – |
Q3 2022 | $342,000 | +8.6% | 14,272 | -1.6% | 0.00% | – |
Q2 2022 | $315,000 | +22.6% | 14,497 | +43.2% | 0.00% | – |
Q3 2021 | $257,000 | -3.0% | 10,121 | -14.0% | 0.00% | – |
Q2 2021 | $265,000 | +18.8% | 11,762 | +4.0% | 0.00% | – |
Q1 2021 | $223,000 | -20.1% | 11,314 | +7.6% | 0.00% | – |
Q4 2020 | $279,000 | – | 10,517 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |